EC Pulmonology and Respiratory Medicine

Review Article Volume 14 Issue 1 - 2025

Pulmonary Hypertension: The Current and Future Scenario

Mohankumar Thekkinkattil*

Senior Consultant Pulmonologist, Department of Pulmonary, Critical Care and Sleep Medicine, OneCare Medical Center, Coimbatore, Tamilnadu, India

*Corresponding Author: Mohankumar Thekkinkattil, Senior Consultant Pulmonologist, Department of Pulmonary, Critical Care and Sleep Medicine, OneCare Medical Center, Coimbatore, Tamilnadu, India.
Received: November 04, 2024; Published:December 24, 2024



Pulmonary hypertension (PH) is a complex and progressive disease characterized by elevated pulmonary arterial pressure, leading to right heart failure. This article reviews the current management strategies for PH, focusing on recent advancements in pharmacological treatments, diagnostic approaches, and intervention techniques. Additionally, the clinical utility of novel biomarkers and the role of risk stratification in guiding therapy are discussed.

 Keywords: Pulmonary Hypertension; Pharmacological Management; Right Heart Failure; Biomarkers; Risk Stratification

  1. Simonneau G., et al. “Haemodynamic definitions and updated clinical classification of pulmonary hypertension”. European Respiratory Journal1 (2019): 1801913.
  2. Galiè N., et al. “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension”. European Heart Journal 1 (2016): 67-119.
  3. Lang RM., et al. “Recommendations for cardiac chamber quantification by echocardiography”. European Heart Journal - Cardiovascular Imaging 3 (2015): 233-270.
  4. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. “ATS statement: guidelines for the six-minute walk test”. American Journal of Respiratory and Critical Care Medicine 1 (2002): 111-117.
  5. McLaughlin VV., et al. “ACCF/AHA 2009 expert consensus document on pulmonary hypertension”. Journal of the American College of Cardiology17 (2009): 1573-1619.
  6. Galiè N., et al. “An overview of the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension”. European Respiratory Journal4 (2015): 879-882.
  7. Rubin LJ., et al. “Bosentan therapy for pulmonary arterial hypertension”. New England Journal of Medicine 12 (2002): 896-903.
  8. Ghofrani HA., et al. “Ambrisentan for the treatment of pulmonary arterial hypertension”. Journal of the American College of Cardiology3 (2005): 529-535.
  9. Galiè N., et al. “Sildenafil for pulmonary arterial hypertension associated with connective tissue disease”. European Respiratory Journal6 (2005): 1102-1109.
  10. Barst RJ., et al. “Prostacyclin therapy for pulmonary arterial hypertension”. Journal of the American College of Cardiology12 (2003): 2119-2125.
  11. Ghofrani HA., et al. “Riociguat for the treatment of chronic thromboembolic pulmonary hypertension”. New England Journal of Medicine4 (2013): 319-329.
  12. Galiè N., et al. “Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension”. New England Journal of Medicine9 (2015): 834-844.
  13. Galiè N., et al. “Task force for diagnosis and treatment of pulmonary arterial hypertension of European Society of Cardiology”. European Respiratory Journal6 (2009): 1219-1263.
  14. Vachiery JL., et al. “Pulmonary hypertension due to left heart diseases”. Journal of the American College of Cardiology25 (2013): D100-D108.
  15. Seeger W., et al. “Pulmonary hypertension in chronic lung diseases”. Journal of the American College of Cardiology25 (2013): D109-D116.
  16. Lang IM and Madani MM. “Update on pulmonary embolism management”. Circulation 24 (2014): 1914-1929.
  17. Feinstein JA., et al. “Balloon pulmonary angioplasty for chronic thromboembolic disease”. Circulation1 (2001): 10-13.
  18. Madani MM., et al. “Pulmonary endarterectomy: patient selection, technical challenges, and outcomes”. Annals of the American Thoracic Society 3 (2016): S240-S247.
  19. Puri V and Patterson GA. “Lung transplantation and pulmonary hypertension”. Current Hypertension Reports 6 (2010): 421-427.
  20. Schermuly RT., et al. “Reversal of experimental pulmonary hypertension by PDGF inhibition”. Journal of Clinical Investigation 10 (2005): 2811-2821.
  21. Klinger JR., et al. “Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report”. Chest 3 (2019): 565-586.
  22. Jackson IJ., et al. “RNA therapeutics: a new frontier in pulmonary hypertension”. Pulmonary Circulation 1 (2022).
  23. van de Veerdonk MC., et al. “Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy”. Journal of the American College of Cardiology 24 (2011): 2511-2519.
  24. Sitbon O., et al. “Selexipag for the treatment of pulmonary arterial hypertension”. New England Journal of Medicine26 (2015): 2522-2533.

Mohankumar Thekkinkattil. "Pulmonary Hypertension: The Current and Future Scenario". EC Pulmonology and Respiratory Medicine  14.1 (2025): 01-10.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net